A case of composite neuroblastoma composed of histologically and biologically distinct clones

Pediatric and Developmental Pathology

Volumn 10, Issue 3, 2007, Pages 229-232

  Sano, Hideki ^a   Gonzalez Gomez, Ignacio ^a   Shi, Qi Wu ^a   Armenian, Saro H ^a   Jubran, Rima F ^a   Shimada, Hiroyuki ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Fluorescent in situ hybridization; International Neuroblastoma Pathology Classification; Mitosis karyorrhexis index; MYCN; Neuroblastoma

Indexed keywords

CATECHOLAMINE; FERRITIN; FLUORESCENT DYE; FORMALDEHYDE; HOMOVANILLIC ACID; LACTATE DEHYDROGENASE; PARAFFIN; VANILMANDELIC ACID; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADRENAL TUMOR; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; CASE REPORT; CATECHOLAMINE URINE LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENE AMPLIFICATION; HISTOLOGY; HUMAN; IN SITU HYBRIDIZATION; INFANT; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE; METASTASIS; MITOSIS; MOLECULAR CLONING; NEUROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; STROMA; TUMOR DIFFERENTIATION; URINALYSIS; BLOOD; CELL CLONE; CLASSIFICATION; FLUORESCENCE IN SITU HYBRIDIZATION; METABOLISM; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME; URINE;

ADRENAL GLAND NEOPLASMS; CLONE CELLS; FEMALE; FERRITINS; HOMOVANILLIC ACID; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; L-LACTATE DEHYDROGENASE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; TREATMENT OUTCOME; VANILMANDELIC ACID;

EID: 34447626289     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/06-06-0117.1     Document Type: Article

References (13)

1. Brodeur GM, Maris JM. Neuroblastoma. In: PA Pizzo, DG Poplack, eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincort Williams & Wilkins, 2002;865-937.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nature Rev Cancer 2003;3:203-216.
3. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
4. Ambros PF, Ambras IM, Kerbel R, et al. Intratumoral heterogeneity of 1p deletions and MYCN amplification in Neuroblastomas. Med Pediatr Oncol 2001;36:1-4.
5. Thorner PS, Ho M, Chilton-MacNeil S, Zielenska M. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Am J Surg Pathol 2006;30:635-642.
6. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364-372.
7. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86:349-363.
8. Peuchmaur M, d'Amore ESG, Joshi VV, et al. Revision of International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274-2281.
9. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer 1995;87:1470-1476.
10. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2699-2708.
11. Kobayashi C, Monforte-Munoz HL, Garbing RB, et al. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/ poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer 2005;103:174-180.
12. Tornoczky T, Kalman E, Kajtar PG, et al. Large cell neuroblastoma: a distinct phenotype with aggressive clinical behavior: new entity? Cancer 2004;100:390-397.
13. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis andtreatment of neuroblastoma. Oncologist 2003;8:278-292.